Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

MLA

Destouches, Damien, et al. “Implication of NPM1 Phosphorylation and Preclinical Evaluation of the Nucleoprotein Antagonist N6L in Prostate Cancer.” Oncotarget, vol. 7, no. 43, Oct. 2016, pp. 69397–411. EBSCOhost, https://doi.org/10.18632/oncotarget.8043.

APA

Destouches, D., Sader, M., Terry, S., Marchand, C., Maillé, P., Soyeux, P., Carpentier, G., Semprez, F., Céraline, J., Allory, Y., Courty, J., De La Taille, A., & Vacherot, F. (2016). Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget, 7(43), 69397–69411. https://doi.org/10.18632/oncotarget.8043

Chicago

Destouches, Damien, Maha Sader, Stéphane Terry, Charles Marchand, Pascale Maillé, Pascale Soyeux, Gilles Carpentier, et al. 2016. “Implication of NPM1 Phosphorylation and Preclinical Evaluation of the Nucleoprotein Antagonist N6L in Prostate Cancer.” Oncotarget 7 (43): 69397–411. doi:10.18632/oncotarget.8043.